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Abstract
Background: Late stage Ovarian Cancer is essentially incurable primarily due to late diagnosis and its inherent
heterogeneity. Single agent treatments are inadequate and generally lead to severe side effects at therapeutic doses.
It is crucial to develop clinically relevant novel combination regimens involving synergistic modalities that target a
wider repertoire of cells and lead to lowered individual doses. Stemming from this premise, this is the first report of
two- and three-way synergies between Adenovirus-mediated Purine Nucleoside Phosphorylase based gene directed
enzyme prodrug therapy (PNP-GDEPT), docetaxel and/or carboplatin in multidrug-resistant ovarian cancer cells.
Methods: The effects of PNP-GDEPT on different cellular processes were determined using Shotgun Proteomics
analyses. The in vitro cell growth inhibition in differentially treated drug resistant human ovarian cancer cell lines
was established using a cell-viability assay. The extent of synergy, additivity, or antagonism between treatments
was evaluated using CalcuSyn statistical analyses. The involvement of apoptosis and implicated proteins in effects
of different treatments was established using flow cytometry based detection of M30 (an early marker of
apoptosis), cell cycle analyses and finally western blot based analyses.
Results: Efficacy of the trimodal treatment was significantly greater than that achieved with bimodal- or individual
treatments with potential for 10-50 fold dose reduction compared to that required for individual treatments. Of
note was the marked enhancement in apoptosis that specifically accompanied the combinations that included
PNP-GDEPT and accordingly correlated with a shift in the expression of anti- and pro-apoptotic proteins. PNP-
GDEPT mediated enhancement of apoptosis was reinforced by cell cycle analyses. Proteomic analyses of PNP-
GDEPT treated cells indicated a dowregulation of proteins involved in oncogenesis or cancer drug resistance in
treated cells with accompanying upregulation of apoptotic- and tumour- suppressor proteins.
Conclusion: Inclusion of PNP-GDEPT in regular chemotherapy regimens can lead to significant enhancement of
the cancer cell susceptibility to the combined treatment. Overall, these data will underpin the development of
regimens that can benefit patients with late stage ovarian cancer leading to significantly improved efficacy and
increased quality of life.
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With the limitations of current monotherapies against
the heterogeneity of cancer, the concept of combining
new and traditional therapies to increase efficacy and
lower side effects is generating significant clinical inter-
est. Cancer targeted molecular chemotherapy, engen-
dered by locally administered Gene Directed Enzyme
Prodrug Therapy (GDEPT) provides a potent strategy for
treating both local and metastatic disease [1,2]., Combin-
ing GDEPT with conventional chemotherapy has the
potential to increase treatment efficacy and is highly rele-
vant clinically, given that the patients being enrolled in
new trials often present with late stage cancer having
failed previous chemotherapy [3]. Such combinations are
of particular relevance for ovarian cancer patients, most
of whom present with late stage disease. With the current
treatment option for these patients of platinum che-
motherapy (cisplatin and carboplatin), only 20-30% of
patients display 5-year survival [4] due to the develop-
ment of chemo-resistant disease. Although combining
platinum therapy with taxanes (paclitaxel, docetaxel)
improves efficacy and survival, the development of the
chemo-resistant phenotype remains an issue [5]. Overall,
combination treatments that are effective in platinum
resistant or platinum sensitive patients are needed. Thus,
we have evaluated the prospective synergies between
Purine Nucleoside Phosphorylase (PNP) mediated
GDEPT and chemotherapeutics, docetaxel and carbopla-
tin in multidrug resistant ovarian cancer cells. PNP-
GDEPT uses the E. coli enzyme, PNP, that can convert
systemically administered, FDA approved pro-drug,
Fludarabine Phosphate (Fludara), into active toxic meta-
bolites (2-Fluoroadenine (2FA) [6]. Particular advantages
of using PNP-GDEPT include (1) its potential to kill both
dividing and quiescent cells through 2FA incorporation
into RNA and DNA [7,8]; (2)t h ep o t e n c yo f“local
bystander” cell killing effects due to passive, gap-
junction independent diffusion of toxic metabolites to
surrounding cells [9]; a strong bystander effect is seen
even when only 1 in 100-1000 cells express the PNP
transgene [10] and (3) PNP-GDEPT mediated regression
of non-transduced cancer cells at distant sites, namely,
‘distant bystander effect’ in immunocompetent mouse
models [11]. Preclinically, activity of PNP-GDEPT against
cancer (prostate, ovarian, melanoma, colon carcinoma,
hepatocellular carcinoma and human glioma) has been
proven [10,12] “(reviewed in [1])” and its advantages over
HSV/tk GDEPT have been shown [13,14]. E. coli PNP
has a different active site and substrate binding features
from its mammalian counterpart ensuring its clinical
relevance [15]. However, the potential application of
PNP-GDEPT for treating ovarian cancer remains rela-
tively unexplored, with only one preclinical study being
described [10].
Carboplatin displays similar efficacy to cisplatin but is
better tolerated and in combination with paclitaxel has
become the standard of care for ovarian cancer patients
[16,17]. However, this treatment can result in cumula-
tive neurotoxicity and myelosupression which may limit
further treatment of these patients. In this study, an
alternative to paclitaxel, docetaxel, was investigated
based on 1) its activity against relapsed ovarian cancer
[18,19] providing symptomatic and survival benefits to
responsive patients [20], 2) lower neuropathy and hyper-
sensitivity [20] and 3) its synergistic interactions with
carboplatin in ovarian cancer cells [21]. Though, doce-
taxel/carboplatin combination displayed good therapeu-
tic outcome with relatively lower neuropathy, toxicities
leading to grade 3-4 neutropenia and other neutropenic
complications have been described [22,23].
We report here the synergistic activity of Adenovirus
(Ad)-mediated PNP-GDEPT and docetaxel and/or carbo-
platin against platinum resistant ovarian cancer cells in
vitro. To attain a molecular insight into PNP-GDEPT
actions and interactions, the protein profile of treated
ovarian cancer cells was generated. The involvement of
cellular apoptosis genes/proteins in the cytotoxicity of
different treatments was assessed given their reported
correlations with therapeutic toxicity [24,25]. We antici-
pate that these data will form a basis for the development
of future combination regimens involving PNP-GDEPT
in the clinic.
2. Methods
2.1 Materials
Docetaxel (Commercial name: Taxotere) (Aventis, Phar-
maceuticals Inc, NJ), Carboplatin (Pfizer, NSW, Australia)
and Fludarabine Phosphate (Fludara), (Schering-Plough,
Germany) were used. Antibodies to Bcl-2, Bik, Bax, Survi-
vin, Caspase-7/9 and PARP were used (source, Additional
file 1(Table S1).
2.2 Cell lines
Ovarian cancer cell lines were maintained either in Dulbec-
co’s Modified Eagle Medium (DMEM) or Roswell Park
Memorial Institute medium-1640 (RPMI) media supple-
mented with 10% foetal calf serum (FCS), 50 U/mL Penicil-
lin and 50 μg/mL Streptomycin (GIBCO/Invitrogen, VIC,
Australia) at 37°C, 5% CO2, in a humidified incubator.
2.3 Viral vectors
Replication defective Ad vectors expressing either Green
Fluorescent Protein (AdGFP) or PNP gene (AdPNP)
under the control of cytomegalovirus (CMV) promoter
were constructed (PNP or GFP genes are cloned in the
E1 region of Ad5 genome), propagated and titrated in
accordance with the instructions from the AdEasy™
adenoviral vector kit (Stratagene, TX, USA).
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Page 2 of 152.4 Assessment of gene expression of Ad-vector
transduced ovarian cancer cells
Cells (24 well plates) infected with Ad-vectors at different
multiplicities of infection (moi, plaque forming units
(pfu)/cell) were assessed for gene expression at 48 h post
infection (pi). GFP: For AdGFP infected cells, the GFP
expression was determined by flow-cytometry using Cell-
Quest™ (Version 3.0) software (Becton Dickinson, San
J o s e ,C A ) .P N P :T h a tt h et o x i ce f f e c t so ft h eP N Pg e n e
are only possible in the presence of Fludara has been
shown unequivocally (with appropriate controls) in our
previous studies and thus, is an acceptable measure of
PNP activity [11,26]. PNP activity, as determined by the
enzymic assay, is accompanied by viral dose dependent
ability of the prodrug, Fludara, to kill the transduced
cells. The conversion of Fludara to its toxic metabolites
by PNP in infected cells was shown by high performance
liquid chromatography. Hence in this study, expression
of PNP (same as used in our previous studies) in AdPNP
infected cells was determined by assessment of cell killing
i nt h ep r e s e n c eo ft h ep r o d r u g ,F l u d a r a ,g i v e n4 8hp o s t
infection using cell viability assays; after 3 to 7 days of
incubation with the prodrug a colorimetric assay using
the REDOX (4-[3-(4-Iodophenyl)-2-(4-nitrophenyl)-2H-
5-tetrazolio]-1, 3-benzeneD i s u l f o n a t e( W S T - 1 )d y e
(Takara Pty Ltd. Otsu Shiga, Japan) was used. At relevant
times, cells were incubated in media containing WST-1
(10: 1) for 2 h and the absorbance measured at 450 nm
(Tecan Sunrise, Phoenix Research Products, USA).
2.5 Assessment of cytoxicity of docetaxel and/or
carboplatin to ovarian cancer cells
Cells treated with different concentrations of docetaxel
and/or carboplatin were assessed for cell viability using
WST-1 assay at different times (see 2.4).
2.6 Evaluation of efficacy of combination of PNP-GDEPT
with docetaxel and/or carboplatin
For synergy experiments, cells (plated in triplicate in 96
well plates, also see Additional file 2 (information, A1)
were infected with either AdPNP or AdGFP. After 48 h,
virus-containing media were replaced with Fludara and/
or docetaxel and/or carboplatin containing media. The
un-infected cells were treated with docetaxel and/or car-
boplatin. After 3 -5 days, cell viabilities were assessed by
WST-1 assay.
2.6.1 Clonogenic assays to assess cytotoxicity of different
treatments
Three days after combination or individual treatments,
cells were re-plated in six-well plates. After 6-9 dou-
blings (~2-3 weeks), cell colonies (≥ 50 cells) were
stained with crystal violet (0.5% in absolute methanol)
and counted.
2.6.2 Evaluation of therapeutic interactions between
modalities
The therapeutic interactions between docetaxel, carbo-
platin and PNP-GDEPT were analysed using the Calcu-
Syn software (Biosoft, Cambridge, United Kingdom)
developed by Chou and Talalay [27,28] that allows statis-
tical evaluation of interactions between 2 or more drugs.
This methodology is based on the median effect equation
correlating drug and its effects and is used to derive an
accurate value of relative potencies of different drugs
(e.g. IC50 etc). The median effect plot (based on the loga-
rithmic form of Chou’s median effect equation) forms
the basis of quantification of synergism, summation and
antagonism of drug combinations: log (fraction affected/
fraction unaffected) vs. log (Dose). A value called Combi-
nation Index (CI) is generated that helps quantify the
interactions for mutually exclusive and non-exclusive
drugs (1983) [27]: A CI < 0.9 implies synergism
(> expected additive effect), CI = 0.90-1.10 implies addi-
tive and a CI > 1.10 shows antagonism (< expected addi-
tive effect) between drugs. Generation of a clinically
significant value, ‘Dose Reduction Index’ (DRI) allows
prediction of the fold reduction in individual modality
dose when used in combination in comparison to when
used alone [29].
2.7 Assessment of apoptosis in response to different
treatments
Treated or untreated cells were analysed for apoptosis
using the M30 CytoDEATH™assay kit (Additional file 1
(Table S1) for source), based on binding of an antibody to
a Caspase-cleaved epitope of cytokeratin 18-cytoskelatal
protein in apoptotic cells and not in viable or necrotic
cells (Peviva AB, Bromma, Sweden). Briefly, cells (1 × 10
5)
(24 well plate) given PNP-GDEPT and/or docetaxel and/
or carboplatin for 48 h were fixed in methanol (-20°C for
30 minutes), washed twice (PBS with 0.1% Tween 20
(PBST) and incubated with 100 μL of M30 CytoDEATH™
(1:100 dilution) or isotype control IgG2b (1:125) antibodies
in incubation buffer (PBS with1% bovine serum albumin
and 0.1% Tween 20). After a wash in PBST, cells were
i n c u b a t e df o r1h( 4 ° C )w i t h1 0 0μL of the fluorescein-
labelled secondary antibody (FITC 1:70) (Silenus,
Melbourne, Australia) and then analysed by flow cytome-
try (FlowJo Version 7.2.2 (Tree Star, Inc., CA).
2.8 Cell-cycle analysis of treated cells
Subconfluent OVCAR-3 cell cultures treated with differ-
ent treatments were harvested at the indicated time
points (0.025% EDTA), washed in ice-cold PBS and
fixed using ice-cold ethanol at 4°C for 30 minutes. After
two washes in PBS, cellular DNA was stained with pro-
pidium iodide solution (50 μg/mL propidium iodide,
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Page 3 of 150.1 mg/mL RNase A and 0.25% Tween 20 in PBS) for
1 h at 37°C. The percentage of cells in the G0/G1, S and
G2/M phases was assessed using flow cytometry.
2.9 Protein expression by Western blot analyses
Proteins in cell lysates (50 μg) from variably treated cells
were resolved on 10% polyacrylamide gel by SDS-PAGE
and then blotted on to nitrocellulose membranes [30].
The blots were incubated overnight in the relevant pri-
mary antibody at concentration recommended by the
manufacturer (source, Additional file 1 (Table S1) fol-
lowed by 1 h incubation with secondary antibody (anti-
rabbit IgG Horse Radish Peroxidase (HRP) conjugated,
1:1000 or anti-mouse IgG HRP, 1:5000 (source, Addi-
tional file 1 (Table S1). The proteins were detected using
an enhanced chemiluminescence (ECL) kit (Piercenet, Il,
USA); treated membranes were exposed to X-ray film
from 1-60 min (as required)-and developed using stan-
dard protocols. The protein bands were quantified from
these films by densitometry using Quantity One software
(Bio-Rad, Hercules, CA).
2.10 Analysis of PNP-GDEPT treated samples by shot gun
proteomics
Untreated OVCAR-3 cells and those treated with PNP-
G D E P T( A d P N Pa tt h em o io f1 0p f u / c e l lf o r4 8h o u r s
and then incubation with Fludara at 1 μg/mL (2.7 μM)
were lysed (3 cycles of freeze thawing) and cell lysates
(50 μgp r o t e i n )w e r er e s o l v e db yS D S - P A G Eu s i n g1 0 %
polyacrylamide gel. After Coomassie blue staining (G-250
stain, Bio-Rad, NSW, Australia), from each lane ~ 10-20
gel pieces were excised and peptides extracted (trypsin
digest) were processed as described [31] (Mass Spectrome-
try Unit, UNSW, Sydney, Australia). The digested peptides
were separated using HPLC (Ultimate 3000 HPLC and
autosampler system, Amsterdam, Netherlands), concen-
trated and desalted and then subjected to mass spectrome-
try (MS) (LTQ FT Ultra (Thermo Electron, Bremen,
Germany).
2.10.1 Protein identification after mass spectrometry
Peptides and proteins in different samples were identified
from extracted tandem mass spectra and peak lists were
generated using Mascot Daemon/extract_msn (Matrix
Science, London, England, Thermo) using the default
parameters submitted to the database search program
Mascot (version 2.1, Matrix Science). They were identified
through searches on non-redundant NCBI protein data-
base (September 2008, see Additional file 2 (information
A2 for details of search parameters and hit criteria). Scaf-
fold (version Scaffold_2.02.01, Proteome Software Inc.,
Portland, OR) was used to validate MS/MS based peptide
and protein identifications (http://www.proteomesoftware.
com/index.html). For statistical analyses, datasets (hit
values based on scaffold analyses) representing PNP-
GDEPT treated and un-treated samples were normalised
by square root transformations; log2 transformation was
carried out and the data plotted as treated vs. un-treated
(data not shown). Subsequently, ratios of log2-transformed
data of both samples were obtained to assess up or down-
regulated proteins. At 95% confidence interval, values of
232.9632 ± 123.8158 were considered significant.
3. Results
To explore the potential synergies between PNP-GDEPT,
docetaxel and carboplatin, ovarian cancer cell lines repre-
senting the most common, adenocarcinoma of epithelial
OC, with variable levels of sensitivity to platinum drug
treatment were selected (Additional file 3 (Table S2)
Based on preliminary evaluations, plating densities that
resulted in logarithmic growth at day 7 (maximum dura-
tion of our experiments) were used. This avoided potential
cell death due to over-confluence/contact-inhibition of
control treated cells prior to the termination of our experi-
ments. In a 96 well format, the optimal numbers of cells/
well were 7000 (OVCAR-3), 3000 (SKOV-3), 10,000 (A-
2780 and 9,000 (Caov-3) (data not shown).
3.1 Efficiency of Ad-transduction in different ovarian
cancer cell lines
Before evaluating the AdPNP-GDEPT, the permissivity of
ovarian cancer cell lines to Ad transductions was evaluated
by assessing the efficiency of Ad/CMV/GFP transductions
in different cell types at 48 h post infection. This showed a
variable level of Ad5-uptake (Figure 1A). At the moi of
100 pfu/cell, OVCAR-3 cells were the most permissive
(% GFP expressing cells ± SEM: 80 ± 5) followed by A-
2780 (15 ± 4) and SKOV-3 cells (12 ± 4). A highly permis-
sive, lung cancer cell line, A - 5 4 9 ,w a su s e da sap o s i t i v e
control. Overall, OVCAR-3 cells displayed the highest Ad-
permissivity at all Ad/CMV/GFP-doses tested, whilst,
Caov-3 cells were almost Ad-refractory with only 3% GFP
expressing cells at the high moi of 500 pfu/cell.
3.2 Bystander effects of PNP-GDEPT correlate with the
efficiency of gene transduction
Evaluation of AdPNP-GDEPT (Fludara: 1 μg/mL (~2.7 μM)
in infected cells showed a dose dependent increase in cyto-
toxicity which correlated with the Ad-permissivity of cell
lines (Figure 1B). The toxic effects (% cell death compared
to untreated controls ± SEM) were maximal in OVCAR-3
cells (50% ± 5 at moi of 4 pfu/cell) followed by SKOV-3
(25% ± 5 at moi of 100 pfu/cell) and A-2780 (15% ± 7 at
moi of 100 pfu/cell) with no effect in Ad-refractory Caov-3
cells. This was also reflected in the IC50 values (± SEM)
[calculated as moi of AdPNP for 50% cytotoxicity]. Interest-
ingly, the ‘bystander effects’ also correlated with the
Ad-permissivity of cells; in highly permissive OVCAR-3
cells, a significant level of cell inhibition was observed at
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Page 4 of 15Figure 1 Panel A. Evaluation of Ad-transduction in different OC cell lines: Cells infected with AdGFP (10-500 pfu/cell) for 48 h were analysed for
GFP expression by flow cytometry. Values represent mean (± SEM) of three experiments. Panel B: Evaluation of bystander effects associated
with PNP-GDEPT in OC cells: Cells infected with AdPNP or AdGFP (control) at different moi followed by the prodrug treatment (Fludara @1 μg/
mL(2.7 μM) were evaluated for cell viability (WST-1 assay) on day 5. Graphs show changes in cell viability relative to control (percentage of sham
infected control cells) for different cell lines. Values represent mean (± SEM) of three experiments. Corresponding IC50 values of PNP-GDEPT in
different ovarian cancer cell lines are also shown.
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Page 5 of 15low viral doses of 1 or 2 moi and up to 90-100% cell growth
inhibition was noted when only 12% (at moi of 10, Figure
1 A )o fc e l l se x p r e s s e dP N P .W h i l s tt h i sd i f f e r e df r o map r e -
vious report [10] that as low as 1% infection was required
to kill all cells, the differences may be due to the expression
system used, and the use of different cell lines.
3.3 Proteins implicated in actions of Ad-PNP GDEPT in
ovarian cancer cells
An insight into the molecular changes underlying the cyto-
toxic effects of PNP-GDEPT may help to understand its
interactions with other modalities. Shot-gun proteomics
analyses were performed on proteins resolved by SDS-
PAGE using cell lysates from untreated and treated
(AdPNP at moi of 10 pfu/cell plus 2.7 μM Fludara) plati-
num-resistant OVCAR-3 cells (see section 2.10). From
these, a list of up- and down-regulated proteins was gener-
ated (Tables 1 & 2); (Note: for description and potential
roles of these proteins, see Additional file 4 (Tables S3 and
S4). Normalisation of data showed symmetrical distribu-
tion, suggesting the similarity of the relative abundance of
most proteins in both samples; however, clearly distinctive
data points representing potentially unique or differentially
abundant proteins were obvious. The stringency of analyses
and the low level variation between the two data
sets suggested the reliability of these data. Ratio values of
treated to untreated cells (range 7925-26529, P < 0.01)
indicated clear upregulation of 16 proteins, to levels signifi-
cantly higher than those predicted for 99% confidence
(232.9632 ± 163.636). The abundant expression of E. coli
PNP, only in PNP-GDEPT treated samples (Scores: 26239
[treated] vs. none [untreated]) provided evidence of its pro-
duction in Ad/CMV/PNP infected samples. Although,
modulated expression of several proteins was seen, only
those present in only one sample and which may have a
potential role in cancer progression or apoptosis, are listed.
Overall, PNP-GDEPT treatment lead to general down-
regulation of proteins involved in (1) cellular metabolism
(lipid, amino acid, carbohydrate and glycolysis) (e.g. poly-
merase (RNA) II (DNA directed), dihydrolipoamide S-
succinyltransferase (E2 component of 2-oxo-glutarate
complex), ribosomal protein L4, mitochondrial trifunc-
tional protein), (2) oncogenesis or cancer progression (cad-
herin, desmoplakin, plakoglobin, karyopherin, spondin,
agrin, GTP binding protein and cadherin 6) and (3) drug
resistance (antiquitin and epoxide hydrolase). An upregula-
tion of proteins involved in apoptosis, tumour suppression
Poly (ADP-ribose) polymerase (PARP) and dead box poly-
peptide 3) and general DNA synthesis was noted.
3.4 Effects of docetaxel or carboplatin treatment on
ovarian cancer cell lines
Growth inhibitory effects of docetaxel against all four
ovarian cancer cells lines at different times were variable
Table 1 List of proteins that displayed significantly reduced expression levels in PNP-GDEPT treated samples
Name of the Protein
Identified
Hit Value
(untreated/treated)
Ratio
Transformed log
(untreated:treated)
1
Keratin 5 13/0 19,306
Keratin 77 12/0 18,502
Cadherin 6 (K-cadherin) 7/0 14,999
Desmoplakin 6/0 14,037
Plakoglobin 3/0 10,000
Spondin 1 3/0 10,000
Dynactin 1 2/0 7,925
Agrin 2/0 7,925
Filaggrin 2/0 7,925
Karyopherin alpha1 2/0 7,925
Antiquitin (ALDH7A1) 2/0 7,925
Epoxide hydrolase 2/0 7,925
Insulysin 2/0 7,925
BRI3 binding protein
(Cervical cancer 1 proto-oncogene-binding protein KG19)
3/0 10,000
Ribosomal protein L4 5/0 12,924
Eukaryotic translation initiation factor 3 subunit 2 (eIF-3 beta) 3/0 10,000
Mitochondrial trifunctional protein, beta subunit 3/0 10,000
Polymerase (RNA) II (DNA directed) polypeptide E 3/0 10,000
Dihydrolipoamide S-succinyltransferase (E2 component of 2-oxo-glutarate complex) 5/0 12,924
v-ral simian leukemia viral oncogene homolog B (ras related; GTP binding protein) (RalB) 2/0 7,925
1Confidence intervals for estimated mean of population: For 0.95 CI: 232.9632 ± 123.8158; For 0.99 CI: 232.9632 ± 163.636
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Page 6 of 15and dose and time dependent (Figures 2A, and Addi-
tional files 5 and 6 (Figure S1 & Table S5). Overall, A-
2780 cells were the most sensitive followed by SKOV-3-,
OVCAR-3- and Caov-3 cells. SKOV-3 and OVCAR-3
cells were chosen for the following experiments based
on their mid-range sensitivity to docetaxel, variable Ad-
permissivity and platinum resistance. This allowed us to
test the synergies in different scenarios in cisplatin resis-
tant ovarian cancer cells, which would be especially rele-
vant for patients resistant to platinum treatment. The
IC50 values for docetaxel (Figure 2A) showed SKOV-3
cells (0.31 nM ± 0.7; R
2:0.96) (Figure 2) to be more doc-
etaxel-sensitive compared to the OVCAR-3 cells (0.61
nM ± 1.1; R
2:0.99).
Use of cisplatin resistant lines would be particularly
relevant to studies involving carboplatin, given its effi-
cacy against cisplatin resistant ovarian cancer [32].
Using a range commonly used in other studies (IC50
range ~5 μM-35 μM [33], carboplatin efficacy was
found to be dose dependent (Figure 2B). However, only
as l i g h td i f f e r e n c ei nt h ec a rboplatin sensitivity (IC50)
was noted (OVCAR-3: 43.12 μM±6 ;R
2:0.97 and
SKOV-3: 38.73 μM ± 4; R
2: 0.96) (Figure 2B).
3.5 PNP-GDEPT, docetaxel and/or carboplatin act
synergistically in ovarian cancer cells in vitro
Cell viability (WST-1-based) evaluations of the cells treated
with the combinations including docetaxel plus carboplatin,
docetaxel plus PNP-GDEPT, carboplatin plus PNP-GDEPT
and combination of all three, in general, showed a signifi-
cant, dose dependent inhibition of cell growth (Additional
file 7 (Figure A2) An assessment of interactions between
modalities through CalcuSyn analysis [27,28] (see methods
for details) of cell viability data generated Combination
Index-Fraction affected (CI-Fa) plots. These data showed
that at the combination ratio (based on potency) of 1:1, the
combined efficacy was additive for the docetaxel/carbopla-
tin combination (Figure 3A and Table 3) (CI:0.89 at IC50
dose; R value 0.99), synergistic when PNP-GDEPT was
combined with either docetaxel (Figure 3B and Table 3)
(CI: 0.21 at IC50; R value 0.93) or carboplatin (Figure 3C
and Table 3) (CI:0.28 at IC50;Rv a l u e0 . 9 6 )a n ds t r o n g l y
synergistic when all three were combined (Figure 3D and
Table 3) (CI:0.11 at IC50; R value 0.94). Statistical analyses
further revealed the “Dose reduction Index (DRI)” values
for each modality in combination to achieve a specific effect
for the two cell lines (Additional file 8 (Table S6). In com-
parison to the individual doses, a dose reduction of up to
~20 fold for PNP-GDEPT, ~27 fold for docetaxel and ~31
fold for carboplatin was predicted to generate 50% cell kill-
ing when used in trimodal combination. In addition to eva-
luation of combinations at the ratio of 1:1, effects were also
evaluated at other ratios e.g. 1:2, 2:1, 1:4 (Additional file 9
(Table S7, CI values). Overall, the trends were similar to
those obtained when drugs were combined at 1:1 ratio with
some variations. To assess whether the drug interactions
lead to long term efficacy, clonogenic assays were per-
formed comparing the effects of trimodal therapy with sin-
gle treatments. Given the fact that carboplatin+docetaxel is
the standard treatment for ovarian cancer patients, long
term efficacy of the trimodal combination would have
direct relevance to the clinic. Treatment of OVCAR-3 cells
with, docetaxel (0.6 nM) or carboplatin (40 μM) or PNP-
GDEPT (AdPNP at moi of 4 pfu/cell plus 2.7 μM Fludara)
alone reduced the number of colonies to ~42%A, 36% and
22% respectively, compared with untreated controls (Figure
4A), whilst the combination of all three reduced colony
growth to 2.3%+/-1.3% (13+/-7 cells vs. 560) (Figure 4A).
This is slightly greater than an additive effect which would
have yielded 3% (0.42 × 0.36 × 0.22 = 0.03) of the controls
(17+/-13 cells compared to 560). Within the experimental
errors of a clonogenic assay, where it is difficult to accu-
rately assess clonal numbers especially in the untreated
cells and due to other factors such as low plating efficiency,
colony size and cancer heterogeneity, these results indicate
an improvement over additive effects. Thus, though the
trends are clear, statistical significance could not be
achieved and the final confirmation of the potential of these
combinations can only be drawn from exhaustive in vivo
evaluations. While, these experiments were beyond the
scope of this specific study, in another study, we have
shown that our in vitro findings comparing synergistic
responses of prostate cancer cells to PNP-GDEPT with
docetaxel (including long term effects as evaluated by
Table 2 List of proteins that displayed significantly increased expression levels in PNP-GDEPT treated samples
Name of the Protein
Identified
Hit Value
(untreated/treated)
Ratio
Transformed log
(untreated:treated)
1
Purine nucleoside phosphorylase [E. coli] 0/37 26,239
Poly (ADP-ribose) polymerase (PARP) 0/4 11,609
Progesterone receptor membrane component 0/3 10,000
Angiotensinogen precursor (Serpin A8) 0/3 10,000
Rab13 0/3 10,000
DEAD Box polypeptide 0/2 7,925
1Confidence intervals for estimated mean of population: For 0.95 CI: 232.9632 ± 123.8158; For 0.99 CI: 232.9632 ± 163.636.
Singh et al. BMC Cancer 2011, 11:368
http://www.biomedcentral.com/1471-2407/11/368
Page 7 of 15A
B
Figure 2 Response of ovarian cancer cells to docetaxel and carboplatin treatments:S K O V - 3a n dO V C A R - 3c e l l se x p o s e dt oar a n g eo f
docetaxel (0.1-316 nM) and carboplatin (1-400 μM) concentrations were evaluated for cell viability using WST-1 assay. Data were plotted as the
percentage of vehicle control treated cells (polysorbate 80+ethanol and sterile water, for docetaxel and carboplatin, respectively) using GraphPad
Prism, version 5. Dose response curves for SKOV-3 and OVCAR-3 cells treated with docetaxel (panel A) or with carboplatin (panel B) for day 5 are
shown. Values represent a mean (± SEM) of three experiments. R2 values > 0.9 suggest that data are reliable and fit the statistical considerations.
The corresponding IC50 values are also shown.
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Page 8 of 15clonogenic assays) were supported by the in vivo outcomes
(Singh et al, Clin Cancer Res. 2011, In press).
3.6 Evaluation of apoptosis in ovarian cancer cells after
different treatments
For these assessments, time points beyond 48 h were not
included as then the significant cellular toxicity (apoptosis/
cell death) observed with combination regimens could
potentially obscure the molecular responses to different
treatments [34]. Evaluation of apoptosis in SKOV-3 cells
treated with docetaxel (1.5 nM), carboplatin (20 μM) and
PNP-GDEPT (AdPNP moi: 150 pfu/cell, 2.7 μMFludara)
(doses showing best efficacy) either alone or in combina-
tion showed that the numbers of apoptotic cells increased
in a time dependent manner in tri-combination treated
cells (Figure 4B). The percentage of M30 positive cells (a
marker of early apoptosis) was maximal in tri-combination
treated cells (49 ± 7) followed by bi-modal (docetaxel/car-
boplatin (17 ± 5), docetaxel/GDEPT (23 ± 6), carboplatin/
GDEPT (31 ± 5), and then individual treatments (PNP-
GDEPT (11 ± 4), docetaxel (14 ± 4), carboplatin (16 ± 6).
As anticipated, apoptosis achieved in Fludara only treated
cells was low (1.5 ± 1), In contrast, when the Fludara was
converted by PNP as in cells treated with the combinations
including PNP-GDEPT, there was a relatively higher num-
ber of apoptotic cells irrespective of the duration of the
treatment.
3.7 Effects of different treatments on cell cycle in treated
cells
Cell cycle analyses of OVCAR-3 cells treated for 48 h with
docetaxel (0.6 nM), carboplatin (10 μM) and PNP-GDEPT
Figure 3 Analysis of combined drug effects of combination treatments. Cells treated with different doses of A. docetaxel and/or carboplatin,
B. PNP-GDEPT (Fludara (1 μg/mL (2.7 μM)) and/or docetaxel, C. PNP-GDEPT and/or carboplatin D. PNP-GDEPT (Fludara (1 μg/mL (2.7 μM)) and/or
docetaxel and/or carboplatin were analysed for cell viability using WST-1 assay on day 5. Graphs representing inhibition of cell growth plotted as a
function of increasing doses of docetaxel and/or carboplatin and/or PNP-GDEPT for OVCAR-3 cells are shown in Additional file 7 (Figure A2). Values
represent mean (± SEM) of three independent experiments. Based on these, Combination Indices (CIs) for different combinations against the
fraction affected (Fa) were plotted to generate CI/Fa plots using Chou and Talalay’s statistical software (CalcuSyn). Data for OVCAR-3 cells are shown.
Similar data were obtained for SKOV-3 cells. Synergy is indicated at CI values of < 0.90, Additive interaction is indicated at CI values of 0.90-1.10 and
antagonism at CI values of > 1.10.
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Page 9 of 15(AdPNP moi: 10 pfu/cell, 1 μg/mL(2.7 μM) Fludara) either
alone or in combination showed a decline in percentage of
cells in G1 phase (20-35%) relative to controls, irrespective
of the treatments applied (Figure 4C). As expected [35,36]
carboplatin (G2/M: 33% ± 9) and docetaxel (G2/M: 43% ±
8) treatments led to an increase in G2/M populations. The
percentage of apoptotic cells (sub-G1phase) for different
treatments was maximal in tri-combination treated cells
(37% ± 6) followed by bi-modal (carboplatin/docetaxel
(28% ± 6) < PNP-GDEPT/docetaxel (32% ± 6) < PNP-
GDEPT/carboplatin (34% ± 7) and then least in single
agent treated cells (carboplatin (9% ± 3) < docetaxel (12%
± 6) < PNP-GDEPT (20% ± 5) with negligible apoptosis in
control treated cells. As with M30 analysis, the percentage
apoptosis was greater when treatments included PNP-
GDEPT. Results were statistically significant when combi-
nation treatment was compared with single treatment or
control treatment (P ≤ 0.05).
3.8 Treatment related effects on pro- and anti-apoptotic
proteins
Mutations in pathways involved in apoptosis modulate
their responses to therapy (e.g. chemoresistance) [reviewed
in [37]. Apoptosis involves initiation (apoptotic stimulus,
e.g., chemotherapeutic or biological agent), effector and
execution phases (which decide the fate of the cell) [38].
Thus, relative expressions of protein members representing
effector phase [Bcl-2, Bik, Bax, Inhibitor of apoptosis (sur-
vivin) and execution phase (caspase-7/9, PARP) were eval-
uated in the treated cells (Figure 5A & 5B) (See Additional
file 10 (Table S8) for their correlation with ovarian cancer
outcomes). A significant but variable down-regulation of
anti-apoptotic genes/proteins (Bcl-2) and up-regulation of
pro-apoptotic genes (Bax, Bik and Bok) was achieved when
modalities were combined, especially when PNP-GDEPT
was included (Figure 5, Additional file 11 (Table S9). Their
expression was relatively littlea f f e c t e db ye i t h e rc a r b o p l a t i n
or docetaxel used alone or together. Survivin was down-
regulated by all combination treatments. Evaluation of
PARP (cleaved and un-cleaved) expression in differentially
treated cells showed the upregulation of un-cleaved (espe-
cially 116 kDa band) and cleaved PARP in response to all
treatments; this was even more in the case with combina-
tion treatments, and highest when PNP-GDEPT was
involved. As Caspase-mediated proteolysis of PARP is a
biochemical marker of apoptosis that denotes the final
stages of apoptosis leading to DNA fragmentation [39], this
indicates that cell killing was occurring in the treated cells.
4. Discussion
This study is the first demonstration of potential syner-
gistic anti-tumour interactions between PNP-GDEPT
based molecular chemotherapy with docetaxel and carbo-
platin in cisplatin-resistant ovarian cancer cells. The data
are significant given that the ovarian cancer cell lines
tested represented subtypes of the epithelial adenocarci-
nomas encountered in over 80% of patients. Synergy eva-
luations in complex biological systems such as cells
grown in culture can be affected by biological variability,
desired dose levels, experimental conditions, such as,
temperature, oxygen tension, pH and finally whether
synergy is treatment schedule dependent or combination
Table 3 Effects of drug interactions between components of different combinations
Modalities Cell Line Combination Index (CI
1) Drug Alone
(×IC50)
Dose Reduction Index (×IC50)R
3 Effect
4
IC
2
50 PNP Doc Car PNP Doc Car
Docetaxel
Carboplatin
SKOV
5 0.96 - 5.01 1.34 - 2.7 1.68 0.98 Additive
+
OVCAR
6 0.89 - 2.76 2.16 - 2.1 2.44 0.99 Additive
+
PNP-GDEPT
Docetaxel
SKOV 0.43 8.22 5.01 - 6.12 3.7 - 0.98 Synergy
+++
OVCAR 0.21 2.03 2.76 - 7.97 10.82 - 0.93 Strong Synergy
++++
PNP-GDEPT
Carboplatin
SKOV 0.29 8.22 - 1.34 12.36 - 4.7 0.97 Strong Synergy
++++
OVCAR 0.28 2.03 - 2.16 5.66 - 9.08 0.96 Strong Synergy
++++
GDEPT Docetaxel
Carboplatin
SKOV 0.37 8.22 5.01 1.34 13.96 8.51 5.3 0.96 Strong Synergy
++++
OVCAR 0.11 2.03 2.76 2.16 19.89 27.02 31.9 0.94 Very Strong Synergy
+++++
1 Combination index values generated when drugs were combined at constant ratio of 1:1 e.g. IC25 of docetaxel with IC25 of carboplatin;
2ED, Effective dose,
which can result in 50, 75 and 90% of cell killing;
3The linear correlation coefficient, R, of the median-effect plot. The acceptable range of ‘R’ values varies with
the type of system used; Enzyme or receptor systems (r > 0.96), tissue culture systems (r > 0.90) and animal experiments (r > 0.85);
4Combination effects, CI value
0.90-1.10 signifies additivity (+); CI 0.7-0.85 moderate synergism (++); CI 0.85-0.9 slight synergies (+++); CI 0.30-0.70 synergism (++++); CI 0.10-0.30 strong
synergism (+++++) and CI 0.01-010 very strong synergism (++++++);
5 represents SKOV-3;
6 represents OVCAR-3
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Page 10 of 15ratio dependent [40]. To address the differences between
measurement units of PNP-GDEPT and chemotherapeu-
tic drugs, the combination ratios were based on the
potency of the individual components (i.e. doses to
achieve a particular effect e.g. IC50). We minimised the
variability and error in data interpretation by evaluating
IC50 values in each experiment for individual modalities
and evaluating potential synergy using the well-recog-
nized Chou and Talalay’s statistical analyses (CalcuSyn
software). For simplicity, mutual exclusivity of the com-
ponent drugs was assumed, as recommended when more
than two drugs are involved [27,40].
The efficiency of docetaxel and carboplatin against the
chosen ovarian cancer cell lines correlated with preclinical
and clinical reports [21,33]. The use of PNP-GDEPT to
treat ovarian cancer has been reported in only one study;
this was against SKOV-3 cells/tumours, although, the pro-
drug, 6-methylpurine-2’-deoxyriboside (MePdR), which is
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Figure 4 Effects of different combination treatments on cell survival, apoptosis and cell cycling: OVCAR-3 or SKOV-3 cells treated with
docetaxel, carboplatin and PNP-GDEPT (with Fludara @ 1 μg/mL (2.7 μM)) either alone or in combination were analysed for cell survival by:
Panel A. Clonogenic assay, Representative photographs show the crystal violet stained colonies of OVCAR-3 cells given different treatments
(docetaxel (0.6 nM), carboplatin (40 μM) and PNP-GDEPT (Ad/CMV/PNP moi of 4 pfu/cell plus 1 μg/mL (2.7 μM) Fludara) either alone or in
combination (in triplicate) in a 6 well plate. The graph and the values in the panel A represents the number of colonies/treatment group and
represent mean (± SEM) of two independent experiments. Values were compared by One Way Anova using Dunnet’s multiple comparison test.
A P value < 0.05 was considered significant (*), however, exact P values for each data set are shown on the graphs. Panel B. Quantitative
estimation of apoptosis in ovarian cancer cells (M30 CytoDEATH assay): SKOV-3 cells were treated with docetaxel (DOC) (3 nM), carboplatin (CAR)
(20 μM) and PNP-GDEPT (Ad/CMV/PNP moi of 200 pfu/cell plus 1 μg/mL (2.7 μM) Fludara) either alone or in combination. Cells harvested 1 and
2 days post treatment were immunostained with M30 cytoDEATH antibody followed by flow cytometry. Graph shows the percent of M30
positive cells (represented apoptotic cell death) on different days post treatment with different modalities (alone or in combination). The
statistical significance of data on the two days was determined by one-way Anova and using Tukey’s multiple comparison tests. Overall P values
and the significant differences between control, mono-, and di- and tri-combination treatments effects are displayed: * = P < 1.01, ** = P <
0.001, *** = P < 0.0001. Panel C. Cell cycle analysis, OVCAR-3 cells treated with different modalities (either alone or in combination; docetaxel (0.6
nM), carboplatin (10 μM) and PNP-GDEPT (Ad/CMV/PNP moi of 10 pfu/cell plus 1 μg/mL (2.7 μM) Fludara) either alone or in combination.) were
assessed for cell cycle progression and apoptosis. Cells were harvested 48 h post treatment, RNA was digested and DNA was stained with
propidium iodide. The histograms represent the fraction of cells in different phases of the cell cycle after different treatments as determined by
flow cytometry. First histogram is representative of different phases of cell cycle in normal untreated cells. While data from one representative
experiment is shown, numbers in each panel show the % distribution of cycling cells as mean ± SEM from three independent experiments.
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Page 11 of 15yet to be FDA approved, was used [10]. Our in vitro data
correlated with their outcomes. The use of FDA approved
Fludara in our study yields a greater clinical relevance to
our findings.
A synergy between modalities means greater efficacy
than the two added together. Synergy between PNP-
GDEPT and docetaxel and/or carboplatin has important
clinical implications; in particular, the ability to use lower
doses of each modality should translate in the clinic to
decreased side effects and an improved quality of life. An
estimation of clinically relevant Dose Reduction Indices
made using the CalcuSyn software (Additional file 8
(Table S6) indicated that significant lowering of individual
doses when used in combination is possible. This is espe-
cially relevant when PNP-GDEPT is given to patients who
have had prior- or are undergoing chemotherapy with
docetaxel and/or carboplatin treatment. Dose reduction of
docetaxel (ranging from ~4-45 fold and carboplatin (from
3-56 fold) was predicted in the trimodal combination with
PNP-GDEPT in the multidrug resistant ovarian cancer
cells under study. Given the toxicities associated with high
dosing of carboplatin or docetaxel alone and in combina-
tion [41,42], these are valuable outcomes especially, for
treating patients with drug refractory cancer. A decrease
in therapeutic doses of PNP-GDEPT could also lower the
total Fludara required; this is important given its potential
immunosuppressive effects. The data obtained in this
study warrant further confirmation in vivo.H o w e v e r ,w e
have previously ratified the in vitro synergy found between
PNP-GDEPT and docetaxel treatment against prostate
cancer cells by in vivo studies, where a decrease in tumour
load both in the prostate and at distant sites in immuno-
competent mice was achieved [Singh P et al, 2011, In
press, Clin Can Res]. Although, synergies were undeniably
proven using combinations in multiple ratios, an assess-
ment of sequential administration of different treatments
was not done. Further exploration of treatments given in
tandem may lead to better synergies; it has been indicated
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Figure 5 Evaluation of treatment related effects on key proteins involved in cellular apoptotic pathways in OVCAR-3 cells: Cell lysates
(50 μg) from treated and untreated cells were analysed by SDS-page/western blotting using the appropriate antibodies (panel A). The protein
bands were quantified by densitometry relative to b-actin (loading control, representative image in the lowest panel) and expressed as the ratio
of specific protein to beta-actin for different treatments (mean ± SEM, n = 2 for two separate experiments) (panel B). Note: only the
representative beta-actin image is shown in panel A. For each protein tested, beta actin controls were included separately in the gel (not shown
in panel A) and the ratios calculated individually (Panel B).
Singh et al. BMC Cancer 2011, 11:368
http://www.biomedcentral.com/1471-2407/11/368
Page 12 of 15that a tumour containing both wild-type p53 cells as well
as p53 mutants could be treated with platinum followed
by a taxane. In such a tumour, platinum would first eradi-
cate the wild-type p53 cells after which the taxane would
kill those with mutant p53 [43].
Synergies between AdPNP-GDEPT and docetaxel
could be partly explained by mutual enhancement sti-
mulated by Ad transduction and docetaxel [44,45].
However, interactions between PNP/Fludara and doce-
taxel or those between carboplatin and AdPNP-GDEPT
are not yet fully understood. Overall, it appears as
though the levels of synergies vary between cell types
and that trimodal therapy may not be as beneficial for
some cell types as expected (e.g. in SKOV-3 cells, bimo-
dal + PNP-GDEPT was as effective as trimodal treat-
ment). A better understanding of these interactions will
help in the design of new regimens in cohorts who have
undergone pre-existing treatment.
In an effort to understand these interactions, protein
studies were performed. Apoptosis was shown to play a
significant role in cell death triggered by combining two
or three modalities (Figure 5). The most effective apopto-
tic stimulus (M30 positive cells, sub G1 phase) occurred
when bimodal combinations involved PNP-GDEPT or
tri-combination treatment was given, accordingly
reflected in the cell killing observed in our studies. Inter-
ference with cell cycle through processes like DNA
damage/microtubule-stabilisation initiates apoptosis.
Both carboplatin and docetaxel led to an accumulation of
cells in G2/M as shown previously [35,36,46]; combining
them led to increased apoptosis (sub G0/G1 phase) sug-
gesting irreversible DNA damage. This may explain the
success of carboplatin/taxane combinations in the clinic
although, long-term data on the development of the
chemoresistant phenotype of ovarian cancers is as yet
inadequate [22,47]. Increasing involvement of pro-/anti-
apoptotic proteins and caspases which generally regulate
the effector phase of apoptosis was observed with multi-
modal treatments in accordance with the corresponding
cell killing synergies. Overall, pro-apoptotic proteins Bax,
Bik, Bok, Cleaved Caspase-7 & -9 were up regulated and
anti-apoptotic, Bcl-2 and Survivin were down regulated
when modalities were combined, albeit to variable levels.
A strong protein expression of both caspase-7 and -9 in
responses to combination therapies suggests that path-
ways involving these Caspases (initiated through release
of cytochrome c from mitochondria) involving the Bcl-2
family of pro- and anti-apoptotic proteins may be more
active in these synergies.
This is the first study to identify protein changes in
response to PNP-GDEPT as obtained in OVCAR-3 cells
using Shotgun Proteomics [47,48]. That PNP-GDEPT
may be acting through involvement in numerous pro-
cesses ultimately leading to shutdown of cell metabolism,
downregulation of some key oncogenes (e.g. cadherin,
desmoplakin, plakoglobin, karyopherin, spondin, agrin)
and genes involved in drug detoxification (e.g. antiquitin,
epoxide hydrolase) with final upregulation of apoptosis
(e.g. PARP) or tumour suppressor proteins (e.g. Dead
box polypeptide 3) is suggestive of pro-apoptotic effects
(Table 3 and Additional file 4 (Tables S3 & S4). Of inter-
est was the downregulation of genes involved in detoxifi-
cation or drug resistance, which may account for the
increased sensitivity of drug resistant OVCAR-3 cells to
docetaxel and carboplatin and for enhanced apoptosis
observed when PNP-GDEPT was included in combina-
tion regimens. This is predictive of its promise for syner-
gies with chemotherapy in the clinic.
Another observation of note is the downregulation of
proteins representing “a desmosome model of carcino-
genesis” (including desmoplakin, cadherins, plakoglobin,
filaggerin) proposed by Chidgey et al [48], in which upre-
gulation of c-myc or Bcl-2 promotes uncontrolled cell
growth. This was supported by the Bcl-2 downregulation
associated with PNP-GDEPT treatment (Figure 5) in our
study. Hence, downregulation of this pathway may be
one of the major features of PNP-GDEPT efficacy. There
was also a possible stress response, with upregulation of
proteins involved in purine and pyrimidine metabolism
coupled with the downregulation of metabolic pathways.
This upregulation of DNA synthesis proteins could also
be Ad-transduction mediated, as this is known to trigger
the cells into synthesis phase.
5. Conclusion
In conclusion, the data indicate that the apoptosis induced
by the three way synergy between docetaxel, carboplatin
and PNP-GDEPT involves the effector phase mediated by
the Bcl-2 family of proteins (pro- and anti-apoptotic) and
execution phase involving cleaved Caspase 9, Caspase 7
and PARP. Overall, there is a strong indication that invol-
vement of PNP-GDEPT correlates with a more active
involvement of pathways involving downregulation of Bcl-
2, survivin and drug resistance proteins, leading to a high
apoptotic index as achieved in the synergies involving
P N P - G D E P T .T h e s ed a t as t r o n g l ys u p p o r tt h eu s eo f
PNP-GDEPT in synergistic treatments in the clinic for
ovarian cancers that show drug resistance to first line
therapies. We anticipate that the information generated in
this study will have potential applications against other
types of cancers.
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significantly up regulated in PNP-GDEPT treated samples compared to
untreated control cells and their role in cancer.
Additional file 5: Figure S1. Response of ovarian cancer cells to
docetaxel treatment: Four ovarian cancer cell lines were exposed to a
range of docetaxel concentrations (0.1-316 nM). WST-1 assay was
performed to analyse cell viability on days 2, 3, 4 and 5. Cell viability was
plotted as the percentage of vehicle control cells (cells treated with
corresponding concentrations of polysorbate 80+ethanol) using
GraphPad Prism. Dose response curves for A-2780, SKOV-3, OVCAR-3 and
Caov-3 as generated on days 2 (black line), 3 (red line), 4 (purple line)
and 5 (brown line) are shown.
Additional file 6: Table S5. Docetaxel (nM) needed to kill 50% of
ovarian cancer cells (IC50).
Additional file 7: Figure S2. Evaluation of cell growth inhibitory effects of
different combinations in OVCAR-3 cells: Cells treated with different doses
of A. docetaxel and/or carboplatin, B. PNP-GDEPT (Fludara (1 μg/mL, 2.7 μM)
and/or docetaxel, C. PNP-GDEPT and/or carboplatin D. PNP-GDEPT (Fludara
(1 μg/ m L ,2 . 7μM) and/or docetaxel and/or carboplatin were analysed for
cell viability using WST-1 assay on day 5. Graphs representing inhibition of
cell growth plotted as a function of increasing doses of docetaxel and/or
carboplatin and/or PNP-GDEPT for OVCAR-3 cells are shown. Some
combinations led to slightly greater cell growth inhibition compared with either
alone. Values represent mean (± SEM) of three independent experiments.
The P values on the graph indicate the significance of trends at various time
points calculated using Two Way Anova analyses.
Additional file 8: Table S6. Dose Reduction Index (DRI) values for
different modalities when used in combination in platinum resistant
ovarian cancer cells.
Additional file 9: Table S7. Interactions between different components
of the combination treatments at different drug combination ratios in
OC cells.
Additional file 10: Table S8. Genes/Proteins expressions and their
correlation with OC outcomes.
Additional file 11: Table S9. Summary of treatment related effects on
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